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Abstract Background Pharmacists work within a highly-
regulated occupational sphere, and are bound by strict legal
frameworks and codes of professional conduct. This reg-
ulatory environment creates the potential for moral distress
to occur due to the limitations it places on acting in con-
gruence with moral judgements. Very little research
regarding this phenomenon has been undertaken in phar-
macy: thus, prominent research gaps have arisen for the
development of a robust tool to measure and quantify
moral distress experienced in the profession. Objective The
aim of this study was to develop an instrument to measure
moral distress in community pharmacists. Setting Com-
munity pharmacies in the United Kingdom. Method This
study adopted a three-phase exploratory sequential mixed-
method design. Three semi-structured focus groups were
then conducted to allow pharmacists to identify and
explore scenarios that cause moral distress. Each of the
identified scenarios were developed into a statement, which
was paired with twin seven-point Likert scales to measure
the frequency and intensity of the distress, respectively.
Content validity, reliability, and construct validity were all
tested, and the questionnaire was refined. Main outcome
measure The successful development of the valid instru-
ment for use in the United Kingdom. Results This research
has led to the development of a valid and reliable instru-
ment to measure moral distress in community pharmacists
in the UK. The questionnaire has already been distributed
to a large sample of community pharmacists. Conclusion
Results from this distribution will be used to inform the
formulation of coping strategies for dealing with moral
distress.
Keywords Community pharmacy  Moral distress 
Professional ethics
Impacts of Findings
• The recognition of moral distress is a significant barrier
to well-being in community pharmacists.
• Tools could be developed to quickly assess both the
frequency and intensity of distress in the population, and
to determine which common scenarios precipitate it.
Introduction
Since the term was first coined to describe some of the
ethical challenges and moral conflicts inherent in the pro-
vision of nursing care [1], the definition of moral distress
has undergone numerous refinements by subsequent
authors [2–9]. However, the following consolidated defi-
nition, proposed by Nathaniel, encapsulates the phe-
nomenon of moral distress in contemporary healthcare:
Moral distress is the pain affecting the mind, body or
relationships that results from a patient care situation,
in which the [practitioner] is aware of a moral
problem, acknowledges moral responsibility and
makes a moral judgement about the correct action,
yet, as a result of real or perceived constraints, par-
ticipates, either by act or omission, in a manner he or
she perceives to be morally wrong [10].
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Studies concerningmoral distress in the nursing profession
have identified significant negative consequences for both
health of theclinicianand thequalityofpatient care.The initial
feelings of anger and outrage that are experienced during the
event often develop into enduring feelings of guilt, hopeless-
ness, loss of confidence, decreased self-esteem, exhaustion
and burnout [11]. Moral distress has also been found to be
associated with an exodus from the profession [12–14].
As the conceptual boundaries of moral distress have
developed, so too has the research interest in the experi-
ences of other professional groups. Although moral distress
was initially delineated within nursing, the concept is rel-
evant across other healthcare professions, as each role
carries its own code of ethics, professional regulations and
legal requirements to be balanced against the individual
practitioner’s moral framework [15]. Subsequent studies
have suggested that moral distress is relevant to and
reported by various disciplines including psychiatric nur-
ses, psychiatrists, podiatrists, psychologists, physiothera-
pists and respiratory therapists [16–21].
Pharmacists working in the UK operate within a highly-
regulated occupational sphere, and are bound by strict legal
frameworks and codes of professional conduct. This reg-
ulatory environment creates the potential for moral distress
to occur due to the limitations it places on acting in con-
gruence with moral judgements. The level of legal regu-
lation of pharmacists compared to other healthcare
professionals is marked: for example, a single error in the
dispensing of medicines may be considered a criminal
offence under s.64(1) of the Medicines Act 1968 [22].
Futhermore, as pharmacists expand their roles to include
more clinical care, there are significantly more opportuni-
ties for ethical and moral problems to arise. Additionally,
community pharmacists are generally more isolated from
support networks than their hospital-based colleagues.
This research builds upon a 2015 literature review and
research agenda by Astbury and co-workers for the study of
moral distress in community pharmacy practice [23].
Aim of the study
The aim of this study was to develop an instrument to
measure moral distress in community pharmacists working
within the UK’s National Health Service (NHS).
Questionnaire development
Overview
The study adopted Myers and Oetzel’s three-phase
exploratory sequential mixed method design [24], as
described by Creswell and Plano Clark [25]. An initial
(qualitative) stage was used to explore moral distress from
the perspective of practicing community pharmacists and
to identify the pharmacy practice situations that they
associate with experiences of moral distress. During the
second stage, the qualitative findings were used to inform
the development of an instrument to capture data regarding
the intensity of moral distress and the frequency of its
occurrence as experienced by community pharmacists. The
instrument was then subjected to content validity testing
before being trialed with a pilot sample in the third
(quantitative) phase of the study. The results of the pilot
sample were then used to carry out construct validity and
reliability testing.
Stage 1
Focus groups
An initial literature search was undertaken of several
electronic databases including PubMed, Scopus, Web of
Science and Google Scholar using combinations of the
search terms ‘‘moral’’, ‘‘ethical’’, ‘‘distress’’, ‘‘stress’’,
‘‘instrument’’, ‘‘scale’’, and ‘‘questionnaire’’. The resulting
literature and existing moral distress instruments were
parsed for clinical practice issues and scenarios with
potential relevance to pharmacists, which were used to
create an initial item pool.
Three semi-structured focus groups were then conducted
to explore whether the practice scenarios highlighted in the
literature review were applicable to community pharma-
cists within their working lives, while simultaneously
providing opportunity for the participants to identify any
other scenarios or issues for item development [26, 27].
The initial group session was conducted in conjunction a
Royal Pharmaceutical Society (RPS) Local Practice Forum
(LPF) for [REDACTED] and [REDACTED], and attracted
17 participants, 13 of which worked primarily within
community pharmacy settings. A further two participants
worked in each of the pharmaceutical industry and the
hospital pharmacy sector, respectively. The topic guide
created from the findings of the literature review was used
to stimulate discussion, and participants were encouraged
to raise any other issues they felt were relevant. Partici-
pants were asked to complete a demographic questionnaire
as part of the registration process for the event. As there
was a notable under-representation of newly-qualified and
junior pharmacists in the initial group, two further focus
groups were convened. The membership of these groups
were made up of community-based practitioners with less
than five, and ten years of post-qualification experience,
respectively. These groups was drawn from alumni of the
four-year Master of Pharmacy qualifying degree program
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at the University of [REDACTED], and newly-qualified
pharmacists employed in its immediate vicinity. Each
session lasted for approximately two hours, and each was
recorded using a proprietary audio-visual recording system.
The audio recordings of the focus group sessions were
transcribed verbatim and thematically coded using the
broad principles of grounded theory [28]. The transcripts
were read through in their entirety several times before
being combined and subjected to open coding. These initial
codes were then organised into categories, each of which
were further divided into themes. [29] An inductive
approach was applied, allowing themes to be derived from
the data using open coding, grouping and categorising.
This enabled abstraction and conceptual mapping to create
a resonant description of the phenomenon [30]. The cate-
gory content was re-examined and compared at various
stages throughout the analysis, and categories felt to cap-
ture the same entity within the data were merged and
reconfigured. Coding was carried out using test–retest
methodology with a 1 month coding interval [31].
Four categories relating to moral distress were identi-
fied, namely: legislative constraints; commercial pressures;
challenges to professionalism; and risk taking & resilience.
Fifteen individual themes, including emergency hormonal
contraception (EHC), whistleblowing, and patient confi-
dentiality were identified within the four categories; of
which thirteen themes in three groups related directly to
causes of moral distress (Fig. 1).
Legislative constraints
It was in the category of legislative constraints that the
potential for moral distress was most immediately obvious:
in the scenarios described by participants, acting in
accordance with their respective consciences would have
resulted in a breach of statutory law. The scenarios that
appeared to be most strongly associated with the experi-
ence of moral distress concerned situations in which the
pharmacists felt unable to lawfully dispense controlled
drugs despite their belief that to do so would be in the
patient’s best interests. The Misuse of Drugs Regulations
2001 place unambiguous procedural requirements on
pharmacists regarding the storage, supply, and use of
medicines that are classified as controlled drugs by the
Misuse of Drugs Act 1971 (as amended) [32, 33].
Contravention of the regulations constitutes a criminal
offence, and may additionally constitute an impairment of
the pharmacist’s fitness to practise under the General
Pharmaceutical Council (Fitness to Practise and Disquali-
fication etc.) Rules 2010 [34]. A finding of impairment by
the General Pharmaceutical Council’s (GPhC) Fitness to
Practise Committee is associated with sanctions ranging
from a warning to removal of the pharmacist from the
Register of Pharmacists. In the focus groups, the pharma-
cists described situations in which they felt confident that
the request made by the patient was legitimate, but that the
required procedural aspects of dispensing could not be
complied with due to absent or incorrectly written pre-
scriptions presented at a time when sourcing a replacement
was logistically difficult (such as on a Sunday or outside
normal business hours). In these situations the perceived
needs of the patient conflicted with the professional
requirement to act within legislative guidelines. When
coupled with an acute awareness of the potential personal
consequences of acting outside of the regulations, the
potential for moral distress is clear.
Practice scenarios that the pharmacists shared often
involved the supply of methadone as part of pharmaco-
logical withdrawal treatment for patients addicted to her-
oin. For pharmacists working consistently from the same
pharmacy the frequent and regular contact with patients
using the methadone service created a heightened sense of
professional involvement in, and engagement with, the
individual’s treatment plan and wellbeing. The pharmacists
spoke of an acute awareness of the possible consequences
for the individual patient of not supplying, and their dis-
tress at being unable to do what they felt was in the
patient’s best interests:
At the end of the day, you’ve got someone who is a
family member, that’s going to be somebody’s
mother, somebody’s father, somebody’s husband,
somebody’s wife. I am never comfortable with not
dispensing [methadone]. If I don’t supply this guy,
he’s going to start using [heroin]. I want to keep the
Commercialism
Challenges to
professionalism
Legislative
constraints
NHS resources
Asserting judgement
Time constraints
Patient autonomy
Whistleblowing
Confidentiality
Controlled drugs
Emergency supply
Off licence drugs
EHC
Link selling
Buy one get one free
Unregulated products
Fig. 1 Categories (left) and themes (right) emerging from initial
thematic analysis
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guy clean, if he starts using again he goes backwards,
and that’s no use to anyone.
Similar legislative and professional constraints are
associated with the supply of EHC and of the supply in an
emergency of prescription-only medicines (POMs) without
a prescription, and with the requirement to breach patient
confidentiality under legislation unrelated to the provision
of healthcare.
Commercialism
In May 2001, the exemption from the general ban on resale
price maintenance enjoyed by proprietary non-prescription
medicines was removed. The Proprietary Association of
Great Britain (PAGB) withdrew their opposition to this
removal following an indication by the Restrictive Prac-
tices Court that it was unsympathetic to the points they
were making [35]. Since that time, pharmacies have been
permitted to offer promotions on the sale of medicines that
were previously prohibited under the Restrictive Practices
Court (Resale Prices) Rules 1976 [36]. This has, in the
opinion of focus group members, lead to a degree of
commercialisation that conflicts with the core professional
values of pharmacy. A number of the pharmacists descri-
bed feeling pressurised to generate and influence purchases
that were not necessarily required or advised. They felt
compelled to promote and facilitate commercial incentives
even when they conflicted with their professional opinion
regarding optimal use of medicines.
Feeling compelled to generate additional sales through
the use of ‘‘three-for-two’’ offers and linked-selling
strategies was cited as a source of moral distress by a
number of participants. In addition, pressure from
employers to promote and sell unregulated products such
as e-cigarettes, homeopathic products and slimming aids
was also cited as a cause of moral distress by some.
I feel I’m expected – due to my professional standing
– to promote the sale or supply of products that have
not been proven effective, or that have been proven
ineffective, so I don’t like selling homeopathic
products … I feel we shouldn’t be selling them in
pharmacies because they are not medicines, they
work contrary to what we are told.
The perceived pressure to prioritise sales targets over
customer needs was echoed throughout the focus groups.
Challenges to professionalism
Six themes in total were identified under the category of
‘‘challenges to professionalism’’, namely: NHS resources;
asserting clinical judgement; time constraints; patient
autonomy; whistleblowing; and confidentiality. Each of
these themes arose from situations in which the pharmacist
was required to ‘‘speak up’’ against a decision that another
party was trying to impose upon them. Unlike the other
categories, in which there were discrete penalties or sanc-
tions for acting with their conscience, the decision-making
process here tends to be affected by the fear less tangible
consequences, such as the erosion working relationships or
the loss of autonomy. The major hurdle that must be
overcome is the assertion of professional judgement in the
face of others who may disagree with it.
For example, one participant was particularly concerned
that some patients’ habitual failure to collect expensive
made-to-order medicines in a timely manner constituted a
waste of NHS resources and public money, but felt unable
to challenge this behaviour:
There are also patients that need some creams, or
some ‘specials’ made up for them and they don’t
come to collect them, and I feel so bad because the
creams they expire [quickly], sometimes in only a
few days. They cost a lot. It happens a lot.
One theme consistently raised in this category was that
of the use by savvy patients of medicines outside their
licensed indications.
Participants raised a number of situations concerning
requests for medicines to be used outside of their officially-
licensed indications. Specifically, the pharmacists high-
lighted situations in which they suspected that medicines
were being sourced for reasons other than those described
by the patient. A focus group participant provided the
following example in which a customer made repeated
visits to the pharmacy to request a specific antihistamine
which the participant suspected was being used as a
sedative for a child:
There is so much going on in your head because, you
know, they are there asking for two or three boxes of
[sedative antihistamine], saying, ‘‘It’s for me and my
husband, for allergies.’’ But I know she has also got
an 8-year-old and you know that this is just a story
they tell to get it.
Acquiescing to the customer’s requests for medicines
for uses outside of licensed indications created feelings of
unease and conflict due to concerns that this constituted
poor professional judgement and practice, and facilitated
the misuse of medicines.
Risk taking and resilience
Not all of the themes identified involved scenarios that
could result in moral distress. The final category described
instances where pharmacists deviated from the rules
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governing from their profession in order to avoid moral
distress. Ka¨lvemark and co-workers also reported instances
in which pharmacists ignored legal and professional
requirements in order to act in congruence with what they
felt was morally right [37]. Such avoidance strategies
straddled each of other categories and their themes. For
example, rather than suffer the moral distress associated
with legally declining to supply a CD in an emergency:
I would dispense it, and I’ve done that before, and I’d
do it again. I’m sure it’s illegal and I accept that, but
at the end of the day I have a duty of care to that
patient.
The most frequently cited motivating value for deciding
to act against regulatory requirements was a concern for the
patient’s welfare.
Newly-qualified pharmacists described feeling particu-
larly vulnerable to experiences of moral distress whilst
navigating the transition from being a student to qualified
pharmacist. This period of role adaptation may be associ-
ated with a sense of generalised anxiety regarding the
marked increase in levels of professional responsibility and
accountability, which, in turn, makes these ‘‘adolescent’’
professionals more likely to experience moral distress as
they strive to adhere to legislative and procedural
requirements. Adolescent professionals may also face an
elevated risk of moral distress due to the additional chal-
lenge of asserting their professional judgement with senior
colleagues [38, 39].
Stage 2
Item generation
Each of the 13 themes relating to practice scenarios were
developed into a statement that described a practice situ-
ation that could generate moral distress. A seven point
Likert scale was chosen for this instrument, with each item
being rated for both intensity and frequency. Each item
asked the same question, ‘‘Have you ever experienced
moral distress as a result of a situation that could be
described in the following way?’’, before going on to
describe a practice scenario in a single statement (Fig. 2).
For example, the scenario for EHC was described as fol-
lows: ‘‘Dispensing emergency hormonal contraception
though this conflicts with my moral beliefs.’’
Content validity
In order to explore the content validity of the instrument,
the item pool and questionnaire format were submitted for
review to a panel of 12 academics working in the
Department of Pharmacy at the University of
Hertfordshire. Reviewers were selected as described by
Grant and Davis [40], taking in account their academic
interests and professional experience of community phar-
macy practice. They were asked to consider and comment
on the clarity of the introductory text and general layout of
the questionnaire. They were also required to evaluate the
relevance of each item to the concept of moral distress,
together with the clarity and conciseness of each item.
Suggestions for additional item domains were also
encouraged to ensure that the item set reflected the con-
struct of moral distress in its totality. Reviewers rated the
relevance of each item on a four point Likert Scale
(1 = not relevant; 2 = somewhat relevant; 3 = quite rel-
evant; 4 = highly relevant). This data was then used to
compute item-level (I-CVI) and scale-level (S-CVI) con-
tent validity index scores (Table 1) [41]. Polit and Beck
recommend that I-CVI values of above 0.9 and S-CVI
values of 0.78 be considered indicative of excellent content
validity [41]. Only item 13 (unregulated products) fell
below the cut-off: however, it was decided to retain this
item in the initial piloting due to the strong emphasis that
was placed on this issue in the focus groups.
Stage 3
Piloting
A hyperlink and invitation to pilot the questionnaire was
emailed to members of two LPFs and the National Institute
for Health Research (NIHR) Clinical Research Network
(CRN) Eastern region. The pilot was closed when a sample
of 50 community pharmacists had completed the self-ad-
ministered online survey. All of the respondents were
working in a community pharmacy or undertook regular
additional work in a community pharmacy setting
(Table 2). An additional response box was added at the end
of the pilot questionnaire inviting comments regarding the
content and structure of the questionnaire. Feedback indi-
cated that one item (unregulated products) lacked clarity
and required rewording. Only one participant did not
complete every aspect of the questionnaire, indicating that
the scenarios held relevance for the respondents.
Reliability
Both the frequency (a = 0.801; n = 50) and intensity
(a = 0.816; n = 50) subscales were found to have a good
level of internal consistency. Inspection of the item total
correlations revealed that only the removal of item 11
(confidentiality) would have created an increase in either
value of a: however, this increase was so small as to be
considered negligible (0.004 and 0.005 for frequency and
intensity, respectively).
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Principal component analysis
The sample used for the pilot study was insufficiently large
to allow either a meaningful principal component analysis
(PCA) or Spearman’s rho to be conducted: however,
returns from a larger probability sample (n = 1340), which
was subsequently distributed, did allow for construct
validity and reliability calculations to be carried out.
The 13 frequency subscale items were subjected to
principal component analysis (PCA) using varimax rotation
following a favourable assessment of sampling adequacy
using the Kaiser–Meyer–Olkin (KMO) measure
(KMO = 0.892) [42]. Bartlett’s test supported the fac-
torability of the correlation matrix (v2(78) = 1869.444,
p\ 0.001) [43]. Criterion for factor loadings was set at
0.30 or greater. PCA revealed the presence of two cate-
gories with eigenvalues exceeding 1.0, explaining a total
43.28% of the variance: the first component accounting for
34.75%; the second accounting for 8.50%. The majority of
items (n = 12) loaded on their respective categories at
above 0.50. There was a moderate positive correlation
between the two categories (r = 0.399). Inspection of the
scree plot revealed a clear point of inflection after the first
component, indicating that only the first component should
Fig. 2 Item 1 (Controlled Drugs) as it appears on the online pilot survey for the questionnaire. Matching 7-point Likert scales for each of the two
dimensions in which moral distress is to be measured are included for each of the 13 items
Table 1 Item-level (I-CVI) and scale-level (S-CVI) content validity index scores for the 13-item moral distress questionnaire
Item Description I-CVI
1 Supply of controlled drugs in the best interest of a patient when legal requirements are unmet 1.00
2 Wasting NHS resources to elicit patient compliance 1.00
3 Actively challenging prescribers regarding prescriptions that contained medicines or doses thought to be inappropriate 1.00
4 Feeling unable to provide an adequate level of service due to time constraints 1.00
5 Professional judgement conflicts with the preferences and wishes of the customer 1.00
6 Commercial values and a pressure to link sell to generate additional sales 0.91
7 Emergency supply of POMs when procedural requirements are unmet 1.00
8 Request from patients for medication for use outside of their licenced indications 0.91
9 Supply of emergency hormonal contraception in conflict with religious or moral beliefs 1.00
10 Professional requirement to engage in whistleblowing though this may be to the detriment of one’s career 1.00
11 Compulsion to release confidential patient data under non-healthcare-related legislation 1.00
12 Commercial incentives that are in opposition to best clinical practice 0.91
13 The sale of unregulated or unproven products 0.75
S-CVI 0.96
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be retained. Parallel analysis provided further support for
the retention of a single component [44]. The first com-
ponent returned a criterion eigenvalue of 1.252 against an
actual value of 4.518 from the PCA, while the second
component returned a criterion value (1.186) that was
significantly higher than that derived from PCA (1.105).
For the 13 intensity subscale items a KMO value of
0.905 was returned. Again, Bartlett’s test returned a
favourable result (v2(78) = 1995.501, p\ 0.001), and the
criterion for factor loadings was set at 0.30 or greater. Two
categories accounted for 37.44 and 8.59% of total variance,
respectively. Eleven items loaded on their respective cat-
egories at above 0.50. As before, there was a moderate
positive correlation between the two (r = 0.422). Inspec-
tion of the scree plot again revealed a clear point of
inflection after the first component indicating that only one
should be retained. This was further supported by parallel
analysis, in which the criterion eigenvalue (1.252) was less
than the derived value (4.867) for the first component only.
The single-category structure was found to be comprised
of the same item variables for both frequency and intensity
subscales. The item clusters on each category indicated that
the original themes were highly correlated, and could be
reduced to a single category.
Construct validity
Construct validity was explored through correlation of
individual item subscale scores with the summated score of
a truncated version of the Ethical Environment Question-
naire (EEQ) [45], which was appended to the moral distress
questionnaire for optional completion. The Cronbach a of
this abbreviated scale was 0.79. Moral distress has been
previously found to be negatively correlated with percep-
tions of ethical environment in studies concerning nurses
and physicians, with high levels of moral distress being
associated with low perceptions of ethical environment
[13, 14, 46]. The relationship between individual intensity
and frequency scores and the EEQ score was explored
using Spearman’s rank correlation coefficient (n = 529).
A statistically significant negative correlation was observed
between the two variables for all but one item on both the
frequency and intensity subscales, with low levels of per-
ceived ethical environment being associated high levels of
moral distress, confirming the predicted relationship.
Discussion
This research has led to the development of a valid and
reliable instrument to measure moral distress in community
pharmacists in the UK. The questionnaire has already been
distributed to a large sample of community pharmacists.
An e-mail inviting pharmacists to participate was suc-
cessfully delivered to the mailboxes of 20,433 recipients.
50.7% (10,360) of recipients opened the e-mail. This
compares to an average of 37.8% (equivalent to 7724
recipients opening the e-mail) for distributions on this list,
and an industry average in the non-profit sector of 20.3%
(4148). 1618 (15.6%) of those recipients who opened the
e-mail clicked through to the survey. The expected
response, based on industry averages, would be 450
(4.3%). A total of 1340 pharmacists completed the survey
following a reminder.
Table 2 Demographic data for the 50 participants in the pilot sample
Pharmacist n = 50
Gender
Female 29
Male 17
Missing 4
Age (years)
Under 25 –
26–35 6
36–45 8
46–55 15
56–65 12
65? 5
Missing 4
Post-qualification experience (years)
Less than 5 3
6–10 4
11–15 6
16–20 7
20? 26
Missing 4
Primary area of pharmacy practice
Community owner 2
Community employee 19
Community locum 18
Primary care 1
Hospital 4
Pharmaceutical industry 1
Academia 1
Missing 4
Regular additional area of pharmacy practice
Community 6
Primary care –
Pharmaceutical industry –
Hospital 2
Academia 1
Missing 41
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In developing a questionnaire of this type, it is important
to consider how the collected data will be treated. There are
two approaches to the interpretation of questionnaires of
this type: individual recording and cumulative scoring.
Although both methods appear throughout the literature,
we contend that the latter is often invalid, due to the nature
of the points on Likert-type scales.
Likert scales are presented as linear scales with the
equidistant differences between interval points: however
the differences in attitudinal intensity between the intervals
cannot be precisely quantified [47]. On the intensity scale,
the separation between mild to moderate and moderate to
severe intensity cannot be assumed to be the same; while
on the frequency subscales, the interval points refer to
easily recognised measures of time that do not have a linear
relationship with each other, but that better reflect how
people recall the recurrence of events. Cumulative scoring,
although common in instruments of this kind [48], is pre-
mised on a known and quantifiable relationship between
intervals. In the former scale, there is no such relationship.
Furthermore, even on the frequency scale, where such a
relationship does exist, two identical cumulative scores can
be derived from significantly different sets of sub-scores.
Conclusion
For these reasons, including an interpretation of individual
item responses has been suggested to provide more a more
meaningful reading of the data [49]. It is intended that each
item of this questionnaire be reported separately, and that
items measuring the moral distress associated with differ-
ent themes in the same category be subsequently compared
with a view to determining which aspects of practice cause
the greatest degree of moral stress.
Factors affecting scenarios occurring with lower fre-
quencies will be examined to determine to determine if
these may be applied to scenarios with high recurrence
rates, with a view to reducing these rates. For example, if
the GPhC’s guidance with regard to one the scenario
generating moral distress is essentially pragmatic, while
another is paternalistic or deontological, an examination of
the consistency of such guidance would be warranted.
Similarly, those scenarios scoring lower for intensity can
be compared, and common factors identified, with a view
to developing coping strategies for higher-scoring
scenarios.
Age, experience, gender, and religious background have
all been shown to have an effect on susceptibility to moral
distress in other healthcare professions
[6, 7, 11, 18, 20, 21, 50], and will be examined in detail. It
is hoped that the results of this large-scale survey will help
in the development of strategies to reduce both the
frequency and intensity of moral distress in the pharmacy
profession.
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